Hengrui PharmaceuticalS SHR6390 approved clinical lying for the treatment of recurrent or metastatic breast cancer
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
yesterday, it was revealed that HengruiMedicine(http://SHR6390 tablets approved for clinical use in the combination of fluorovis group treatment HR-positive, HER2-negative after endocrine therapy progression of recurrent or metastatic breast canceras well as recurrent or metastatic breast cancer used to treat HR-anaquzole in combination with HR-anaquzole, HER2-negative, endocrine-based progressionAbout SHR6390
SHR6390 is a CDK4/6 selective inhibitor for the treatment of malignant tumorsThe world's first CDK4/6 inhibitor, adeveloped by PfizerInc.,(http:// was approved by theFDA(http://in February 2015 through accelerated review and is now available in the European Union, Japan and other countries and regions, the FDA has approved three CDK 4/6 inhibitorsdrug (http:// , including Pfizer's Palbociclib (2015/2/3), Novartis' Ribociclib (2017/3/13) and Lilly's Abemaciclib (2017/9/28), with global sales of $41.18, 235.55 billion in 2018 At present, only Pfizer's a CDK4/6 inhibitor was approved for market, and a total of 25 drug declarations in other CDK4/6 inhibitors in research were declared clinical or in clinical stage, while The SHR6390 tablets of Hengrui Pharmaceuticals were preemptively entered Phase III clinical studies
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
